The present study was designed to provide clinical confirmation of Cb2's value as a new
approach in the prevention of increased vascular permeability and hemoconcentration, both
signs of OHSS in humans, and in order to explore its mechanism of action. To this end, a
prospective, randomized, placebo-controlled study was designed in which Cb2 was employed in
women at risk of OHSS after gonadotropin administration for ART. Simultaneously, ovarian
perfusion was assessed in these patients using MR pharmacokinetic modeling.
Phase:
Phase 3
Details
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA